68Ga/177Lu-FAP-2286 是一种新开发的肿瘤显像剂，具有可视化和治疗肿瘤基质的潜力。本研究的目的是评估 68Ga-FAP-2286 PET/CT 和 18F-FDG PET/CT 诊断晚期肺癌的有效性。在这项前瞻性研究中，接受 68Ga-FAP-2286 和 18F PET/CT 检测的肺癌患者-分析2022年9月至2023年6月期间的FDG PET/CT检查。病变摄取被转换为SUVmax。采用配对T检验来比较SUVmax，并记录两种方法检测到的阳性病灶的数量。总共对31名参与者（中位年龄：56岁）进行了评估。原发灶中 68Ga-FAP-2286 的摄取量显着高于 18F-FDG（分别为 9.90 ± 5.61 vs. 6.09 ± 2.84，P < 0.001）、淋巴结（分别为 7.95 ± 2.75 vs. 5.55 ± 1.59） ，P=0.01）和骨转移（分别为 7.74 ± 3.72 与 5.66 ± 3.55，P=0.04）。此外，使用 68Ga-FAP-2286 PET/CT 检测淋巴结的灵敏度优于 18F-FDG PET/CT [分别为 100% (137/137) vs. 78.8% (108/137)]，以及骨转移[分别为 100% (384/384) vs. 68.5% (263/384)]。然而，使用两种方式对原发肿瘤的检测灵敏度相当[均为100% (13/13)]。与 18F-FDG PET/CT 相比，68Ga-FAP-2286 PET/CT 表现出更好的肺癌病灶检测能力特别是在淋巴结和骨转移中，为 177Lu-FAP-2286 治疗的功效提供了令人信服的影像学证据。版权所有 © 2024 Xiang、Zhang、Tan、Zhang、Li、Yan、Ma 和 Chen。

The 68Ga/177Lu-FAP-2286 is a newly developed tumor imaging agent that shows potential for visualizing and treating tumor stroma. The objective of this research was to evaluate the effectiveness of 68Ga-FAP-2286 PET/CT and 18F-FDG PET/CT in diagnosing advanced lung cancer.In this prospective study, patients with lung cancer who underwent 68Ga-FAP-2286 and 18F-FDG PET/CT examinations between September 2022 and June 2023 were analyzed. Lesion uptake was converted to SUVmax. A paired T-test was used to compare the SUVmax, and the number of positive lesions detected by the two methods was recorded.In total, 31 participants (median age: 56 years) were assessed. The uptake of 68Ga-FAP-2286 was significantly higher than that of 18F-FDG in primary lesions (9.90 ± 5.61 vs. 6.09 ± 2.84, respectively, P < 0.001), lymph nodes (7.95 ± 2.75 vs. 5.55 ± 1.59, respectively, P=0.01), and bone metastases (7.74 ± 3.72 vs. 5.66 ± 3.55, respectively, P=0.04). Furthermore, the detection sensitivity of lymph nodes using 68Ga-FAP-2286 PET/CT was superior to that with 18F-FDG PET/CT [100% (137/137) vs. 78.8% (108/137), respectively], as well as for bone metastases [100% (384/384) vs. 68.5% (263/384), respectively]. However, the detection sensitivity for primary tumors using both modalities was comparable [100% (13/13) for both].Compared to 18F-FDG PET/CT, 68Ga-FAP-2286 PET/CT demonstrated better lesion detection capabilities for lung cancer, particularly in lymph nodes and bone metastases, providing compelling imaging evidence for the efficacy of 177Lu-FAP-2286 treatment.Copyright © 2024 Xiang, Zhang, Tan, Zhang, Li, Yan, Ma and Chen.